FDA-approved Monotherapies
FDA-approved Combination Therapies
Intron A
Roferon

Infergen
Pegasys
PEG-Intron
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Factors Associated with Long-term Liver Complications after Spontaneous HCV Clearance or Successful Treatment

By Liz Highleyman

Hepatitis C virus (HCV) infection can lead to long-term liver complications including cirrhosis and hepatocellular carcinoma (HCC). While elimination of HCV -- either due to spontaneous
clearance or successful antiviral treatment -- has been associated with reduction in the rate of liver fibrosis progression, less is known about the longer-term effects of viral clearance.

As reported in the August 2007 Journal of Viral Hepatitis, 1641 hepatitis C patients recruited from 8 European centers in 1996-1997 (the HENCORE cohort) were re-analyzed 5-7 years after enrollment. The occurrence of decompensated cirrhosis, HCC, and liver transplantation was analyzed in relation to different host and viral factors.

Results

93% of the patients who had cleared the virus spontaneously or after antiviral therapy remained HCV RNA negative during follow up and may be considered "cured."

Among patients who were sustained virological responders at inclusion, just 2.3% developed liver complications during follow up, compared with 31% of treatment non-responders.

Older age at the time of infection and presence of the human leukocyte antigen (HLA) DRB1*1201-3 allele were possibly associated with a higher rate of progression to decompensated cirrhosis or HCC.

Decompensated cirrhosis might be further associated with male sex, non-response to previous therapy, and lack of the HLA DRB1*1301 allele, while HCC seems to be associated with the presence of the HLA DQ02 allele.

Conclusion

"Long-term follow up of HCV patients indicates that virological response persists over time and is associated with a very low incidence of liver complications," the study authors wrote.

They added that, "Advanced age at inclusion, advanced age at infection, viral genotype 1, non-response to previous therapy and possibly some specific HLA alleles are factors independently associated with a faster rate of progression towards liver complications."

08/24/07

Reference
P Pradat, HL Tillmann, S Sauleda, and others. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. Journal of Viral Hepatitis 14(8): 556-563. August 2007.




 

 

 

 

 

 

 

 

 

 

 

 

 

 

 





Google_______________